IL3RA and acute myeloid leukemia: Another phase I study of CSL362 (anti-IL-3Rα/CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia in complete remission or complete remission with incomplete platelet recovery at high risk for early relapse is ongoing (NCT01632852, Clinical Trials Gov).